Use of risperidone as augmentation treatment for major depressive disorder

Annals of Pharmacotherapy

Volumn 45, Issue 1, 2011, Pages 95-100

  Owenby, Ryan K ^a   Brown, Lindsey T ^b   Brown, Jamie N ^a  

^a DURHAM VA MEDICAL CENTER   (United States)

^b CAMPBELL UNIVERSITY   (United States)

Author keywords

Augmentation; Major depressive disorder; Risperidone

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOPAMINE RECEPTOR; MIRTAZAPINE; NEFAZODONE; PLACEBO; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE;

AKATHISIA; ARTICLE; ATTENTION DISTURBANCE; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INCREASED APPETITE; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; MALAISE; META ANALYSIS (TOPIC); MONOTHERAPY; PANIC; PARKINSONISM; PRIORITY JOURNAL; RELAPSE; REMISSION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TARDIVE DYSKINESIA; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; RISPERIDONE; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 78751565420     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P397     Document Type: Article

References (23)

1. Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al. Pharmacotherapy principles & practice. New York, NY: The McGraw-Hill Companies, Inc., 2008:569-82.
2. World Health Organization. www.who.int/mental-health/management/ depression/definition/en/ (accessed 2010 Apr 19).
3. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005;62: 1097-106.
4. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
5. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004;61:669-80.
6. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009;70:16-25.
7. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci 2000;68:29-39.
8. Product information. Risperdal (risperidone). Titusville, NJ: Ortho-Mc- Neil-Janssen Pharmaceuticals, June 2009.
9. Barrett E, Blonde L, Clement S, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27: 596-601.
10. Lebovitz HE. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q 2003;74:277-90.
11. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35.
12. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006;31:2505-13.
13. Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008;16:21-30.
14. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder. Ann Intern Med 2007;147:593-602.
15. Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69:1228-36.
16. Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009;43:205-14.
17. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60:256-9.
18. Viner MW, Chen Y, Bakshi I, Kamper P. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J Clin Psychopharmacol 2003;23:104-6.
19. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (2nd edition). Am J Psychiatry 2000;157(4 suppl):1-45.
20. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-53.
21. Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine- controlled study. J Clin Psychiatry 2009;70:526-39.
22. Bauer M, Pretorius HW, Constant E, et al. Extended-release quetiapine fumarate as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-9.
23. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65:267-72.